Find Clinical Trial
Study of the effect of trimetazidine MR 35 mg (2 tabs/day) on the emergence of choroidal neovascularisation in age-related macular degeneration: a multicentre, randomised, double-blind, placebo-controlled, phase III study in 1100 patients treated for 3 to 5 years
← Back
| Study Phase |
Phase 3 |
| Therapeutic Area |
Other |
| Indication | Age related Macular Degeneration |
| Sponsor | Institut de Recherches Internationales Servier (I.R.I.S) |
| Active substance/ Medical device |
TRIMETAZIDINE, |
| Active Substance Code | S006790 |
| Protocol Code | MC3-06790-001 |
| ISRCTN Code | ISRCTN99532788 |
Documents and links
| Results summary | READ MORE  |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
